Stellar stock: buy or sell?

SBOT stock price: $298,098.00 7.00% At close on June 28th, 2019

Updated on:
June 28th, 2019

5

Stellar Biotechnologies shares crossed up the simple moving average line of 200 days today and closed at $298,098.00. On June SBOT collapsed a spooky -26.83%.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia.

Should I buy Stellar stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Stellar Biotechnologies stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean SBOT will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Stellar stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for SBOT stock for the last 30 days.

Stellar stock analysis

Daily outlook

Stellar Biotechnologies broke up the SMA line of 200d today and closed at $298,098.00, skyrocketed a 7,508,665.74%.

Stellar Biotechnologies crossed up the SMA line of 200d today and closed at $298,098.00. Since last June when SMA100d and SMA200d crossed up, SBOT price gained $298,092.80 per share (5,732,553.85%). From a daily perspective, SBOT is in a short term uptrend after plotting its last bottom ($1.03, on June) higher than the previous bottom, and its last top ($6.18, on June) also over the previous top. Now trading in between its last bottom and last top SBOT might consolidate in a plain range, waiting to break out over $6.18 or down under $1.03.

SBOT stock chart (daily)

Weekly outlook

Stellar shares broke up the SMA line of 200d, closing at $298,098.00. Early June SBOT plummed a bloodcurdling -85.71% in just one week.

In a weekly time frame, Stellar Biotechnologies stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, SBOT might consolidate in a flat-base, waiting to break out over or down under . Since late May when SMA20w and SMA40w crossed up, SBOT price gained $298,096.88 per share (26,615,792.86%).

SBOT stock chart (weekly)

Stellar stock price history

Stellar stock went public on September 10th, 2010 with a price of $28.001. Since then, SBOT stock grew a 1,064,535.70%, with a yearly average of 133,067.00%. If you had invested $1,000 in Stellar stock in 2010, it would worth $10,645,357.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Stellar stock historical price chart

SBOT stock reached 52-week highs on June at $6.18, and all-time highs 2014-08-28 with a price of 165.2.

Stellar stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' SBOT stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price prediction for Stellar stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Stellar presented its financial report, posting a shining climb for the Earnings per Share (EPS) ratio. Analyst expected $-0.23 per share, but Stellar posted $-0.26.
SBOT earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.11n/a
2017-Q2-n/a-0.12n/a
2017-Q32017-12-01-0.11n/an/a
2017-Q42018-02-08n/an/an/a
2018-Q12018-07-03n/an/an/a
2018-Q22018-08-08-0.45-0.38n/a
2018-Q32019-01-04n/an/an/a
2018-Q42019-02-05-0.23-0.26n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Stellar Biotechnologies annual turnover slipped an awful -7.20% to $0.21 million dollars from $0.23 marked in 2017. Nonetheless, its income margin (compared to sales) plunged to -2,378.56%, that is $-5.04 million.

To have an up to date picture of the financial situation of Stellar, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Stellar TTM sales up to December 2018 were $0.24 and earnings were $-5.04 M USD. If we compare this TTM figures with the last reported annuality, we can review Stellar Biotechnologies business evolution since September 2018: Annual revenues up to December, compared to lastest yearly report, climbed a dazzling 15.36%. Likewise, profit margin (net income/sales) skyrocketed at -2,378.56%.

SBOT annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$0.55 M-$-14.89 M-2729.8%-
2014$0.05 M-90.32%$1.13 M2136.7%-107.57%
2015$0.76 M1,337.29%$-2.84 M-374.7%-352.06%
2016$1.27 M67.62%$-5.03 M-395.2%76.79%
2017$0.23 M-82.05%$-5.03 M-2203.7%0.09%
2018$0.21 M-7.20%$-5.04 M-2378.6%0.16%
TTM $0.24 M15.36%$-5.04 M-2063.8%0.10%

Quarterly financial results

Stellar reported $0.05 M in sales for 2018-Q4, a -2.26% less compared to previous quarter. Reported quarter income marked $-1.41 million with a profit margin of -2,650.61%. Profit margin collapsed a -569.78% compared to previous quarter when profit margin was -2,080.84%. When comparing turnover to same quarter last year, Stellar Biotechnologies sales marked an extraordinary growth and skyrocketed a 158.86%. Looking back to recent quarterly results, Stellar Biotechnologies posted 2 negative quarters in a row.
SBOT quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$0.06 M-$-1.10 M-1745.5%-
2017-Q2$0.02 M-67.42%$-1.22 M-5941.9%10.91%
2017-Q3$0.00 M-85.97%$-1.22 M-42393.7%0.08%
2017-Q4$0.02 M611.35%$-1.40 M-6837.3%14.73%
2018-Q1$0.06 M212.65%$-1.35 M-2111.6%-3.44%
2018-Q2$0.07 M14.05%$-1.16 M-1583.3%-14.48%
2018-Q3$0.05 M-25.73%$-1.13 M-2080.8%-2.39%
2018-Q4$0.05 M-2.26%$-1.41 M-2650.6%24.51%

Stellar ownership

When you are planning to invest in a company, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Stellar, of all outstanding shares are owned by its staff.

The following table compares ownership indicators for other stocks related to Stellar Biotechnologies:

SBOT
Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

Stellar summary

Friday, June 28th, 2019
Open$1.11
Close$298098.00
Day range$1.03 - $1.17
Previous close$3.97
Session gain7,508,665.74%
Average true range$1.00
50d mov avg$5,963.35
100d mov avg$2,982.27
200d mov avg$1,491.72
Daily patternlt06a
Weekly pattern lt06a

Stellar performance

To better understand Stellar performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Stellar against in the following table:
Stock3m6m12m
SBOTStellar Biotechno...25921500.00%33494100.00%16200900.00%

Stellar competitors

Unfortunately, we could not find any public company that could be defined as Stellar Biotechnologies competitor. This doesn't mean Stellar Biotechnologies does not have any competitor in the market, it's just we could not detected it.